CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Purchased by Benjamin Edwards Inc.

Benjamin Edwards Inc. grew its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 37.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 45,062 shares of the company's stock after purchasing an additional 12,359 shares during the quarter. Benjamin Edwards Inc. owned approximately 0.05% of CRISPR Therapeutics worth $1,774,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in CRSP. Highline Wealth Partners LLC purchased a new position in CRISPR Therapeutics during the fourth quarter worth about $39,000. Western Pacific Wealth Management LP raised its position in shares of CRISPR Therapeutics by 100.0% during the 4th quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company's stock valued at $39,000 after buying an additional 500 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new position in CRISPR Therapeutics in the third quarter worth $40,000. Spire Wealth Management raised its holdings in shares of CRISPR Therapeutics by 303.7% during the 4th quarter. Spire Wealth Management now owns 1,970 shares of the company's stock valued at $78,000 after buying an additional 1,482 shares in the last quarter. Finally, MCF Advisors LLC bought a new stake in CRISPR Therapeutics in the 4th quarter worth approximately $80,000. 69.20% of the stock is currently owned by institutional investors.

CRISPR Therapeutics Stock Down 2.3%

NASDAQ:CRSP traded down $0.87 during mid-day trading on Tuesday, reaching $36.72. The company's stock had a trading volume of 877,965 shares, compared to its average volume of 2,166,212. CRISPR Therapeutics AG has a 1 year low of $30.04 and a 1 year high of $67.88. The firm has a market capitalization of $3.17 billion, a PE ratio of -8.40 and a beta of 1.88. The stock has a fifty day moving average of $38.03 and a 200-day moving average of $42.64.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported ($1.58) EPS for the quarter, missing analysts' consensus estimates of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. During the same period last year, the company posted ($1.43) EPS. CRISPR Therapeutics's revenue was up 71.6% compared to the same quarter last year. On average, analysts expect that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts recently commented on CRSP shares. HC Wainwright reaffirmed a "buy" rating and set a $65.00 target price on shares of CRISPR Therapeutics in a report on Thursday, February 13th. Cantor Fitzgerald reiterated a "neutral" rating on shares of CRISPR Therapeutics in a report on Wednesday, February 19th. Chardan Capital dropped their target price on CRISPR Therapeutics from $84.00 to $82.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. Citigroup lowered their price objective on CRISPR Therapeutics from $89.00 to $82.00 and set a "buy" rating for the company in a research report on Tuesday, February 18th. Finally, Truist Financial raised their target price on shares of CRISPR Therapeutics from $100.00 to $120.00 and gave the stock a "buy" rating in a report on Wednesday, February 12th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $71.75.

Insider Transactions at CRISPR Therapeutics

In related news, General Counsel James R. Kasinger sold 2,850 shares of the firm's stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total transaction of $120,897.00. Following the completion of the sale, the general counsel now directly owns 77,530 shares in the company, valued at approximately $3,288,822.60. This trade represents a 3.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Samarth Kulkarni sold 18,360 shares of the company's stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total transaction of $1,013,472.00. Following the completion of the transaction, the chief executive officer now directly owns 171,613 shares in the company, valued at $9,473,037.60. The trade was a 9.66% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 32,381 shares of company stock valued at $1,608,243 over the last ninety days. Insiders own 4.30% of the company's stock.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.